Materialise Q4 2025: Medical 3D Printing Drives 16% Growth as Company Beats Expectations

The Numbers

Materialise NV (NASDAQ: MTLS) delivered a solid finish to 2025, with Q4 revenue climbing 6.8% to €70.2 million. But the real story is the medical segment — up 16.3% year-over-year to €37 million, now accounting for more than half of total revenue.

Gross margins improved to 58.1% from 55.4% a year earlier, and adjusted EBIT hit €3.98 million (5.7% of revenue). Full-year 2025 revenue reached €267 million.

Medical Leads the Way

The Belgian company's medical division has become its growth engine. Specialising in patient-specific implants, anatomical models, and surgical planning software, Materialise Medical is riding the wave of personalised healthcare.

CEO Brigitte de Vet-Veithen highlighted the segment's momentum on the earnings call, noting that the company recently added PEEK cranio-maxillofacial implants to its portfolio alongside its established titanium offerings.

2026 Guidance

Looking ahead, Materialise guided for 2026 revenue of €273–€283 million, representing 2–6% growth. The company completed a dual listing on Euronext Brussels in November 2025, expanding its investor base in Europe.

What This Means for the Industry

Materialise's results are a bellwether for the 3D printing services market. Several trends emerge:

• Medical is outpacing industrial — Whilst manufacturing services face headwinds, healthcare applications continue to accelerate.
• Software is sticky — Deferred software revenues grew €5.9 million in Q4 alone, showing strong recurring revenue.
• Services consolidation — As the Wohlers Report 2026 noted, services now dominate the AM market, and Materialise is well-positioned.

The Bottom Line

For a company founded in 1990, Materialise shows it can still grow. The medical pivot has proven prescient — personalised implants and surgical guides are exactly where additive manufacturing delivers unique value. Expect this trend to continue as regulatory pathways for patient-specific devices mature globally.